Cargando…

Moving from clinician-defined to patient-reported outcome measures for survivors of high-grade glioma

BACKGROUND: Persons with high-grade glioma face both neurological and cancer-related symptoms from the tumor itself and its treatment affecting their daily lives. Survival alone is not an adequate outcome, the quality of the survivorship experience needs to be regarded with equal importance. Patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenlund, Lena, Degsell, Eskil, Jakola, Asgeir Store
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711557/
https://www.ncbi.nlm.nih.gov/pubmed/31692481
http://dx.doi.org/10.2147/PROM.S179313
_version_ 1783446538300686336
author Rosenlund, Lena
Degsell, Eskil
Jakola, Asgeir Store
author_facet Rosenlund, Lena
Degsell, Eskil
Jakola, Asgeir Store
author_sort Rosenlund, Lena
collection PubMed
description BACKGROUND: Persons with high-grade glioma face both neurological and cancer-related symptoms from the tumor itself and its treatment affecting their daily lives. Survival alone is not an adequate outcome, the quality of the survivorship experience needs to be regarded with equal importance. Patient-reported outcome (PRO) measures can be used to evaluate treatment effects and symptom management interventions. PURPOSE: The aim of this review was to identify the use, challenges, and potential of PRO measures in survivors of high-grade glioma. METHODS: A narrative expert opinion review was performed on the subject. In addition to our own experiences we searched PubMed, Cumulative Index to Nursing and Allied Health Literature, the Cochrane Library, and PsycINFO for brain tumor-specific PRO measures used in the population of adult patients with high-grade glioma, both original articles and reviews were included. RESULTS: There are several PRO measures that have been validated for patients with primary brain tumors including high-grade glioma. PRO measures are used both in clinical trials to evaluate the effect of treatment on health-related quality of life, and in daily clinical practice for holistic needs assessment and symptom management. Common PRO measures used for patients with high-grade glioma are European Organization for Research and Treatment of Cancer general instrument for patients with cancer together with brain tumor module, Functional Assessment of Cancer Therapy-Brain, and MD Anderson Symptom Inventory for Brain Tumor. Neurologic and cognitive disorders often occur in patients with high-grade glioma, which affects patients’ ability to self-report over time, making it more challenging in this population. PRO as a primary outcome seems underutilized. CONCLUSION: For clinical research, PRO measures need to be used together with other clinical outcome measures rather than replacing traditional outcome measures. Moving to more use of PRO measures in survivorship care has potential to improve patient-caregiver-healthcare team communication, symptom management, and quality of care. Implementing PROs in survivorship care should also involve caregivers and a response based on the results.
format Online
Article
Text
id pubmed-6711557
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67115572019-11-05 Moving from clinician-defined to patient-reported outcome measures for survivors of high-grade glioma Rosenlund, Lena Degsell, Eskil Jakola, Asgeir Store Patient Relat Outcome Meas Review BACKGROUND: Persons with high-grade glioma face both neurological and cancer-related symptoms from the tumor itself and its treatment affecting their daily lives. Survival alone is not an adequate outcome, the quality of the survivorship experience needs to be regarded with equal importance. Patient-reported outcome (PRO) measures can be used to evaluate treatment effects and symptom management interventions. PURPOSE: The aim of this review was to identify the use, challenges, and potential of PRO measures in survivors of high-grade glioma. METHODS: A narrative expert opinion review was performed on the subject. In addition to our own experiences we searched PubMed, Cumulative Index to Nursing and Allied Health Literature, the Cochrane Library, and PsycINFO for brain tumor-specific PRO measures used in the population of adult patients with high-grade glioma, both original articles and reviews were included. RESULTS: There are several PRO measures that have been validated for patients with primary brain tumors including high-grade glioma. PRO measures are used both in clinical trials to evaluate the effect of treatment on health-related quality of life, and in daily clinical practice for holistic needs assessment and symptom management. Common PRO measures used for patients with high-grade glioma are European Organization for Research and Treatment of Cancer general instrument for patients with cancer together with brain tumor module, Functional Assessment of Cancer Therapy-Brain, and MD Anderson Symptom Inventory for Brain Tumor. Neurologic and cognitive disorders often occur in patients with high-grade glioma, which affects patients’ ability to self-report over time, making it more challenging in this population. PRO as a primary outcome seems underutilized. CONCLUSION: For clinical research, PRO measures need to be used together with other clinical outcome measures rather than replacing traditional outcome measures. Moving to more use of PRO measures in survivorship care has potential to improve patient-caregiver-healthcare team communication, symptom management, and quality of care. Implementing PROs in survivorship care should also involve caregivers and a response based on the results. Dove 2019-08-23 /pmc/articles/PMC6711557/ /pubmed/31692481 http://dx.doi.org/10.2147/PROM.S179313 Text en © 2019 Rosenlund et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Rosenlund, Lena
Degsell, Eskil
Jakola, Asgeir Store
Moving from clinician-defined to patient-reported outcome measures for survivors of high-grade glioma
title Moving from clinician-defined to patient-reported outcome measures for survivors of high-grade glioma
title_full Moving from clinician-defined to patient-reported outcome measures for survivors of high-grade glioma
title_fullStr Moving from clinician-defined to patient-reported outcome measures for survivors of high-grade glioma
title_full_unstemmed Moving from clinician-defined to patient-reported outcome measures for survivors of high-grade glioma
title_short Moving from clinician-defined to patient-reported outcome measures for survivors of high-grade glioma
title_sort moving from clinician-defined to patient-reported outcome measures for survivors of high-grade glioma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711557/
https://www.ncbi.nlm.nih.gov/pubmed/31692481
http://dx.doi.org/10.2147/PROM.S179313
work_keys_str_mv AT rosenlundlena movingfromcliniciandefinedtopatientreportedoutcomemeasuresforsurvivorsofhighgradeglioma
AT degselleskil movingfromcliniciandefinedtopatientreportedoutcomemeasuresforsurvivorsofhighgradeglioma
AT jakolaasgeirstore movingfromcliniciandefinedtopatientreportedoutcomemeasuresforsurvivorsofhighgradeglioma